AU2002239578A1 - Enhanced efficacy and safety of genotoxic therapy by p38 mapk modulation - Google Patents

Enhanced efficacy and safety of genotoxic therapy by p38 mapk modulation

Info

Publication number
AU2002239578A1
AU2002239578A1 AU2002239578A AU3957802A AU2002239578A1 AU 2002239578 A1 AU2002239578 A1 AU 2002239578A1 AU 2002239578 A AU2002239578 A AU 2002239578A AU 3957802 A AU3957802 A AU 3957802A AU 2002239578 A1 AU2002239578 A1 AU 2002239578A1
Authority
AU
Australia
Prior art keywords
mapk
modulation
safety
enhanced efficacy
genotoxic therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002239578A
Inventor
Dmitry V. Bulavin
Albert J. Fornace Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU2002239578A1 publication Critical patent/AU2002239578A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002239578A 2000-11-07 2001-11-06 Enhanced efficacy and safety of genotoxic therapy by p38 mapk modulation Abandoned AU2002239578A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24691200P 2000-11-07 2000-11-07
US60/246,912 2000-11-07
PCT/US2001/047669 WO2002038143A2 (en) 2000-11-07 2001-11-06 Enhanced efficacy and safety of genotoxic therapy by p38 mapk modulation

Publications (1)

Publication Number Publication Date
AU2002239578A1 true AU2002239578A1 (en) 2002-05-21

Family

ID=22932754

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002239578A Abandoned AU2002239578A1 (en) 2000-11-07 2001-11-06 Enhanced efficacy and safety of genotoxic therapy by p38 mapk modulation

Country Status (2)

Country Link
AU (1) AU2002239578A1 (en)
WO (1) WO2002038143A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1709965A3 (en) 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediate diseases
WO2005077983A2 (en) * 2004-02-05 2005-08-25 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Modulating p38 kinase activity
FR2874619B1 (en) * 2004-08-25 2006-11-17 Centre Nat Rech Scient Cnrse NOVEL PHOSPHORYLATED PHOSPHATASE SEQUENCES OF CDC25B PHOSPHATASE, ANTIBODIES DIRECTED THEREFROM AND USES THEREOF
CN109528720B (en) * 2019-01-08 2021-03-30 浙江大学 Application of SB203580 in preparation of antitumor drugs and antitumor drugs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863729A (en) * 1996-07-09 1999-01-26 Washington University DNA sequences encoding human TcAK1 kinase
AU6394500A (en) * 1999-07-30 2001-02-19 Basf Bioresearch Corporation Native cdc25 substrates, compositions and uses related thereto
WO2001057206A2 (en) * 2000-02-03 2001-08-09 Ribozyme Pharmaceuticals, Inc. Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme

Also Published As

Publication number Publication date
WO2002038143A2 (en) 2002-05-16
WO2002038143A3 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
AU2001297911A1 (en) Magnetic therapy devices and methods
EP1304137A3 (en) Anti-tachycardia pacing methods and devices
AU2002218012A1 (en) Electromagnetically induced anesthesia and sensory stimulation
AU2001260513A1 (en) Microcapsule well treatment
AU2001275340A1 (en) Integrated active flux microfluidic devices and methods
WO2003028558A8 (en) Methods and devices for heart valve treatments
AU2001253479A1 (en) Targeted therapeutic agent release devices and methods of making and using the same
AU2003256555A1 (en) Controlled delivery of active ingredients and sensory markers
AU2002356530A1 (en) Medical devices comprising nanomaterials and therapeutic methods utilizing the same
HK1068546A1 (en) Combination therapy comprising zd6474 and taxane
AUPR839001A0 (en) Dosage form, device and methods of treatment
AU2002346504A1 (en) Therapeutic protein and treatments
AU2002332841A1 (en) Amusement rides and methods
AU2001233296A1 (en) Establishing and maintaining therapeutic hypothermia
AU2002254342A1 (en) Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
AU2001265253A1 (en) Treatment of hiv using hyperthermia
AU2002252976A1 (en) Hydrazones and their therapeutic use
AU2002258600A1 (en) Uses of targeted oxidative therapeutic formulation in arteriosclerosis
EP1379236A4 (en) Treatment of tics, tremors and related disorders
AU2002231206A1 (en) Treatment of depression
AU2001222215A1 (en) Lumbago treating girdle
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
AUPR736801A0 (en) Advanced games and puzzles
AU2002239578A1 (en) Enhanced efficacy and safety of genotoxic therapy by p38 mapk modulation
AU2002227247A1 (en) Biofilm therapy process and elements